Skip to content
2000
image of The Intricacies of Polypharmacy and Drug Interactions in Schizophrenia Treatment

Abstract

Introduction

Polypharmacy is frequently practiced in the management of schizophrenia due to its chronic nature, recurrent relapses, and associated comorbidities. While combining psychotropic medications may benefit patients with treatment-resistant symptoms, it poses risks such as drug–drug interactions (DDIs), adverse effects, and reduced medication adherence. The absence of uniform prescribing standards further complicates clinical decision-making.

Methods

This narrative review was conducted using a scoping methodology. Databases including PubMed, Scopus, and Web of Science were searched for English-language publications from 2000 to 2024. Search terms included “schizophrenia,” “polypharmacy,” “drug–drug interactions,” “clinical outcomes,” and “pharmacogenetics.” Eligible sources included clinical trials, observational studies, systematic reviews, and treatment guidelines. Exclusion criteria were non-English articles, gray literature, and individual case reports.

Results

Polypharmacy is reported in 30–60% of individuals with schizophrenia, especially in institutionalized or treatment-resistant populations. Treatment regimens often involve multiple antipsychotics along with adjunctive antidepressants or mood stabilizers. This approach is associated with increased risks of metabolic syndrome, cardiovascular events (e.g., QT prolongation), extrapyramidal symptoms, and decreased adherence. Interindividual variability in pharmacogenetics further affects drug efficacy and safety. Innovative approaches like genotype-guided therapy and computerized clinical decision-support systems are promising but not yet widely implemented.

Discussion

Although polypharmacy may offer symptomatic relief in specific scenarios, it requires careful management due to its potential to cause harm. Rational prescribing, close monitoring, and attention to individual patient factors such as pharmacogenetic profiles are essential to optimize therapy.

Conclusion

Ensuring a balance between therapeutic benefit and adverse effects is crucial when employing polypharmacy in schizophrenia treatment. Integrating personalized medicine strategies, regular monitoring, and deprescribing practices when feasible can enhance clinical outcomes and patient safety.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002382047250930160449
2025-10-10
2025-12-14

  • From This Site

    /content/journals/cdm/10.2174/0113892002382047250930160449
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Suhail K. Ghauri S. Phenomenology of delusions and hallucinations in schizophrenia by religious convictions. Ment. Health Relig. Cult. 2010 13 3 245 259 10.1080/13674670903313722
    [Google Scholar]
  2. Dold M. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst. Rev 2015 1 1 CD009831.Jan 16 10.1002/14651858.CD009831.pub2 25592299
    [Google Scholar]
  3. Wal P. Dwivedi J. Wal A. Vig H. Singh Y. Detailed insight into the pathophysiology and the behavioral complications associated with the Parkinson’s disease and its medications. Future J. Pharm. Sci. 2022 8 1 33 10.1186/s43094‑022‑00425‑5
    [Google Scholar]
  4. Strawn JR. Stahl, SM Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD). In: Case Studies: Stahl’s Essential Psychopharmacology: Children and Adolescents. Cambridge University Press 2023 259 278 10.1017/9781009049719.017
    [Google Scholar]
  5. Buckley P.F. Hwang M.Y. Comorbid psychiatric disorders in schizophrenia: More than just a chance co-occurrence. In: Obsessive-Compulsive Symptoms in Schizophrenia. Springer 2015 3 10 10.1007/978‑3‑319‑12952‑5_1
    [Google Scholar]
  6. Alba Palé L. Electroconvulsive therapy and psychotropic concomitant treatment: Study of clozapine and mood stabilizers. Eur. Neuropsychopharmacol. 2016 26 Suppl. 2 S480 10.1016/S0924‑977X(16)31485‑7
    [Google Scholar]
  7. Ayano G. Psychotropic medications metabolized by cytochromes P450 (CYP) 2D6 enzyme and relevant drug interactions. Clin. Pharmacol. Biopharm. 2016 5 4 10.4172/2167‑065X.1000162
    [Google Scholar]
  8. Smulevich A. Romanov D. Long-term course of negative symptoms in schizophrenia. In: Managing Negative Symptoms of Schizophrenia. Oxford Academic 2020 39 50 10.1093/med/9780198840121.003.0003
    [Google Scholar]
  9. Budenholzer B. Review: In multiepisode schizophrenia, most antipsychotic drugs improve symptoms; adverse effects vary by drug. Ann. Intern. Med. 2019 171 10 JC57.a 10.7326/ACPJ201911190‑057 31739340
    [Google Scholar]
  10. Samajdar S. Tripathi S. Clinical pharmacological reconciliation, review and feedback in Ensuring Patient Safety. Authorea 2023 10.22541/au.168318730.05878882/v1
    [Google Scholar]
  11. Ferraris A. Angriman F. Barrera T. Penizzotto P. Faerman S. Rivadeneira W. Chiessa A. Mura G. Pollán J.A. Szmulewicz A.G. Prevalence of central nervous system-active polypharmacy in a cohort of older adults in Argentina. BJPsych Open 2024 10 6 e190 10.1192/bjo.2024.798 39468835
    [Google Scholar]
  12. Muthanna F.M.S. Ibrahim H.K. A descriptive retrospective study of the prevalence of antipsychotic polypharmacy (app) among schizophrenia patients in Malaysia. Research Square 2022 10.21203/rs.3.rs‑1507228/v1
    [Google Scholar]
  13. John A.P. Gee T. Alexander S. Ramankutty P. Dragovic M. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service. Australas. Psychiatry 2014 22 6 546 550 10.1177/1039856214546672 25147317
    [Google Scholar]
  14. Mojtabai R. Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch. Gen. Psychiatry 2010 67 1 26 36 10.1001/archgenpsychiatry.2009.175 20048220
    [Google Scholar]
  15. Correll C. Rummel-Kluge C. Corves C. Kane J. Leucht S. Antipsychotic combinations versus monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr. Res. 2008 102 1-3 35 10.1016/S0920‑9964(08)70110‑5
    [Google Scholar]
  16. Kreyenbuhl J.A. Valenstein M. McCarthy J.F. Ganoczy D. Blow F.C. Long-term antipsychotic polypharmacy in the VA health system: Patient characteristics and treatment patterns. Psychiatr. Serv. 2007 58 4 489 495 10.1176/ps.2007.58.4.489 17412850
    [Google Scholar]
  17. Goff D.C. Dixon L. Antipsychotic polypharmacy: Are two ever better than one? Am. J. Psychiatry 2011 168 7 667 669 10.1176/appi.ajp.2011.11020314 21724670
    [Google Scholar]
  18. Tiihonen J. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients. JAMA Psychiatry 2017 10.26226/morressier.5971be85d462b80290b52546
    [Google Scholar]
  19. Barnes T.R.E. Drake R. Paton C. Cooper S.J. Deakin B. Ferrier I.N. Gregory C.J. Haddad P.M. Howes O.D. Jones I. Joyce E.M. Lewis S. Lingford-Hughes A. MacCabe J.H. Owens D.C. Patel M.X. Sinclair J.M.A. Stone J.M. Talbot P.S. Upthegrove R. Wieck A. Yung A.R. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2020 34 1 3 78 10.1177/0269881119889296 31829775
    [Google Scholar]
  20. Naber D. Lambert M. Aripiprazole: A new atypical antipsychotic with a different pharmacological mechanism. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004 28 8 1213 1219 10.1016/j.pnpbp.2004.06.020 15588748
    [Google Scholar]
  21. López-Muñoz F. Álamo C. Active metabolites as antidepressant drugs: The role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front. Psychiatry 2013 4 102 10.3389/fpsyt.2013.00102 24062697
    [Google Scholar]
  22. Ameer M.A. Patel P. Saadabadi A. Neuroleptic medications. In: StatPearls. StatPearls Publishing 2024
    [Google Scholar]
  23. Ayres J.K. Maani C.V. Milrinone. In: StatPearls. StatPearls Publishing 2018
    [Google Scholar]
  24. Goodwin G. Evidence-based guidelines for treating bipolar disorder Revised third edition recommendations from the British Association for Psychopharmacology. J. Psychopharmacol 2016 30 6 495 553 10.1177/0269881116636545 26979387
    [Google Scholar]
  25. Rosenheck R.A. Open forum: effectiveness versus efficacy of second-generation antipsychotics: Haloperidol without anticholinergics as a comparator. Psychiatr. Serv. 2005 56 1 85 92 10.1176/appi.ps.56.1.85 15637198
    [Google Scholar]
  26. Dixon L.B. Stroup T.S. Medications for first-episode psychosis: Making a good start. Am. J. Psychiatry 2015 172 3 209 211 10.1176/appi.ajp.2014.14111465 25727529
    [Google Scholar]
  27. Beaulieu J.M. Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 2011 63 1 182 217 10.1124/pr.110.002642 21303898
    [Google Scholar]
  28. Dold M. Fugger G. Aigner M. Lanzenberger R. Kasper S. Dose escalation of antipsychotic drugs in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr. Res. 2015 166 1-3 187 193 10.1016/j.schres.2015.04.024 26008883
    [Google Scholar]
  29. McGlashan T.H. Zipursky R.B. Perkins D. Addington J. Miller T. Woods S.W. Hawkins K.A. Hoffman R.E. Preda A. Epstein I. Addington D. Lindborg S. Trzaskoma Q. Tohen M. Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 2006 163 5 790 799 10.1176/ajp.2006.163.5.790 16648318
    [Google Scholar]
  30. Simpson E.H. Kellendonk C. Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010 65 5 585 596 10.1016/j.neuron.2010.02.014 20223196
    [Google Scholar]
  31. Goossen R.B. Freeman D.J. Satchell A.M. Urquhart B.L. Monitoring clozapine. Ther. Drug Monit. 2003 25 4 469 472 10.1097/00007691‑200308000‑00009 12883231
    [Google Scholar]
  32. Sabé M. Pallis K. Solmi M. Crippa A. Sentissi O. Kaiser S. Comparative effects of 11 antipsychotics on weight gain and meta-bolic function in patients with acute schizophrenia J. Clin. Psychiatry 2023 84 2 22r14490. 10.4088/JCP.22r14490 36752753
    [Google Scholar]
  33. Lin J.H. Transporter-mediated drug interactions: Molecular mechanisms and clinical implications. In: Drug-Drug Interactions. CRC Press 2019 545 566 10.1201/9780429131967‑12
    [Google Scholar]
  34. Preskorn S.H. Drug-Drug Interactions (ddis) in psychiatric practice, part 2: Strategies to minimize adverse outcomes from unintended ddis. J. Psychiatr. Pract. 2018 24 5 341 347 10.1097/PRA.0000000000000335 30427821
    [Google Scholar]
  35. Hendset M. Molden E. Knape M. Hermann M. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther. Drug Monit. 2014 36 1 80 85 10.1097/FTD.0000000000000018 24232129
    [Google Scholar]
  36. Chen W-Y. Shen Y-C. Complex drug interaction of carbamazepine, fluvoxamine and clozapine in a patient with bipolar depression. Arch. Clin. Psychiatry 2019 46 6 171 171 10.1590/0101‑60830000000220
    [Google Scholar]
  37. Wysokiński A. Blood levels of glucose and insulin and insulin resistance in patients with schizophrenia on clozapine monotherapy. Diabetes Metab. Syndr. 2014 8 4 236 241 10.1016/j.dsx.2014.09.020 25311817
    [Google Scholar]
  38. Kearns B. Cooper K. Cantrell A. PMU13 schizophrenia treatment with second-generation antipsychotics: A MULTI-country evaluation of the costs of cardiovascular and metabolic adverse events and weight gain. Value Health 2020 23 S605 10.1016/j.jval.2020.08.1225
    [Google Scholar]
  39. Mok N.S. Lo Y.K. Tsui P.T. Lam C.W. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug. J. Cardiovasc. Electrophysiol. 2005 16 12 1375 1377 10.1111/j.1540‑8167.2005.00299.x 16403073
    [Google Scholar]
  40. Masuo K. Lambert W. Calcium channel blockers in obesity-related hypertension. Metab. Agents Med. Chem. 2010 10 2 66 75 10.2174/187152210793177027
    [Google Scholar]
  41. Rana A.Q. Morren J.A. Neuroleptic malignant syndrome (NMS). In: Neurological Emergencies in Clinical Practice. Springer 2013 109 111 10.1007/978‑1‑4471‑5191‑3_13
    [Google Scholar]
  42. Gardner D.M. Teehan M.D. Tardive dyskinesia and other late-onset movement disorders. In: Antipsychotics and Their Side Effects. Cambridge University Press 2010 123 128 10.1017/CBO9780511919237.023
    [Google Scholar]
  43. Puspita O. Zullies Ikawati, Antipsychotic-associated neuroleptic malignant syndrome (NMS) in schizophrenia patients: A narrative review. Indones J. Pharmacol. Ther. 2024 5 1 10.22146/ijpther.9878
    [Google Scholar]
  44. Mitterauer B. Loss of function of glial gap junctions may cause severe cognitive impairments in schizophrenia. Med. Hypotheses 2009 73 3 393 397 10.1016/j.mehy.2009.04.003 19435655
    [Google Scholar]
  45. Sharifi H. Hasanloei M. Mahmoudi J. Polypharmacy-induced drug-drug interactions; Threats to patient safety. Drug Res. 2014 64 12 633 637 10.1055/s‑0033‑1363965 24500732
    [Google Scholar]
  46. The American Psychiatric Association practice guideline for the treat-ment of patients with schizophrenia; American Psychiatric Associa-tion 2020 10.1176/appi.books.9780890424841
  47. Biglino G. Layton S. Wray J. When we meet in a clearing: Making research accessible to patients and patient experience accessible to clinicians. J. Patient Exp. 2019 6 4 333 335 10.1177/2374373518819441 31853491
    [Google Scholar]
  48. Correll C.U. Rummel-Kluge C. Corves C. Kane J.M. Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr. Bull. 2009 35 2 443 457 10.1093/schbul/sbn018 18417466
    [Google Scholar]
  49. Rangnekar A.S. Fontana R.J. Managing drug-drug interactions with boceprevir and telaprevir. Clin. Liver Dis. 2012 1 2 36 40 10.1002/cld.10 31186844
    [Google Scholar]
  50. Wal A. Wal P. Vig H. Jain N.K. Rathore S. Krishnan K. Srivastava A. Treatment of Parkinson’s disease: Current treatments and recent therapeutic developments. Curr. Drug Discov. Technol. 2023 20 5 e120523216834 10.2174/1570163820666230512100340 37183475
    [Google Scholar]
  51. Preskorn S.H. Drug-Drug Interactions (ddis) in psychiatric practice, part 8: Relative receptor binding affinity as a way of understanding the differential pharmacology of currently available antidepressants. J. Psychiatr. Pract. 2020 26 1 46 51 10.1097/PRA.0000000000000445 31913969
    [Google Scholar]
  52. Tao D. Wang H. Xia F. Ma W. Pancytopenia due to possible drug-drug interactions between low-dose methotrexate and proton pump inhibitors. Drug Healthc. Patient Saf. 2022 14 75 78 10.2147/DHPS.S350194 35607639
    [Google Scholar]
  53. Salander P. Including physiological variables in studies might confuse more than clarify. Patient Educ. Couns. 2014 94 1 140 10.1016/j.pec.2013.08.026 24051047
    [Google Scholar]
  54. Schwartz L.M. Woloshin S. The drug facts box: Making informed decisions about prescription drugs possible In: Better Doctors, Better Patients, Better Decisions; MIT Press Direct 2011 233 242 10.7551/mitpress/9143.003.0020
    [Google Scholar]
  55. Dwivedi J. Kaushal S. Wal P. J C, D. Sharma A Nathiya D. Gasmi A. A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications Curr. Drug Metab 2025 10.2174/0113892002358291250401190533 40248924
    [Google Scholar]
  56. Patient lift manufacturer plans training video to augment Safety Alert. Biomed. Saf. Stand. 1990 20 21 163 10.1097/00149078‑199012010‑00003
    [Google Scholar]
  57. Bousman C.A. CYP2D6 testing to guide risperidone and aripiprazole therapy. Lancet Psychiatry 2019 6 5 362 364 10.1016/S2215‑0366(19)30138‑5 31000416
    [Google Scholar]
  58. Benson P.R. Factors associated with antipsychotic drug prescribing by southern psychiatrists. Med. Care 1983 21 6 639 654 10.1097/00005650‑198306000‑00006 6134878
    [Google Scholar]
  59. Veras R.P. Contemporary care model for older people: An urgent need. Rev. Bras. Geriatr. Gerontol. 2020 23 5 230065 10.1590/1981‑22562022025.230065.en
    [Google Scholar]
  60. Dima A. Wazir A. Clark-Castillo R. Zakopoulos I. Smith S. Gaughran F. Factors influencing the length of stay in forensic psychiatric settings: A systematic review. BMC Health Serv. Res. 2024 24 1 400 10.1186/s12913‑024‑10863‑x 38553762
    [Google Scholar]
  61. Ras T. Holdman R. Matthews D. Ramadhan fasting for people living with chronic illness: A narrative literature review. S. Afr. Fam. Pract. 2024 66 1 e1 e6 10.4102/safp.v66i1.5805 38299530
    [Google Scholar]
  62. Luo H. Lau K.K. Wong G.H.Y. Chan W.C. Mak H.K.F. Zhang Q. Knapp M. Wong I.C.K. Predicting dementia diagnosis from cognitive footprints in electronic health records: A case–control study protocol. BMJ Open 2020 10 11 e043487 10.1136/bmjopen‑2020‑043487 33444218
    [Google Scholar]
  63. Palermo S. Frailty in the elderly - Understanding and managing complexity. IntechOpen 2022 10.5772/intechopen.83157
    [Google Scholar]
  64. Kingsbury S.J. Yi D. Simpson G.M. Psychopharmacology: Rational and irrational polypharmacy. Psychiatr. Serv. 2001 52 8 1033 1036 10.1176/appi.ps.52.8.1033 11474046
    [Google Scholar]
  65. Dwivedi J. Kumar P. Sachan P. Singh C. Saxena B. Wal A. Wal P. Phyto-pharmacological Potential of Aegle marmelos (L.) for neurological disorders: Progress and prospects. Recent Adv. Food Nutr. Agric. 2024 16 1 12 30 10.2174/012772574X289517240222045916 38468524
    [Google Scholar]
  66. Veras R.P. Contemporary care model for the aged: An imminent need. Rev. Bras. Geriatr. Gerontol. 2024 24 1 230038 10.1590/1981‑22562024027.230038.pt
    [Google Scholar]
  67. Goyal A. Bergh S. Engedal K. Kirkevold M. Kirkevold Ø. Norwegian version of the rating anxiety in dementia scale (RAID-N): A validity and reliability study. Aging Ment. Health 2016 20 9 101 109 10.1080/13607863.2016.1220921 27584559
    [Google Scholar]
  68. Pharmacists in Practice Pharmacists in Practice Pharmacists are the success story of general practice, and they are here to stay. Pharm. J. 2023 310 1 190102 10.1211/pj.2023.1.190102
    [Google Scholar]
  69. Kelly J. Polypharmacy: Increasing medication adherence. Preprint 2023 10.33015/dominican.edu/2023.NURS.RP.19
    [Google Scholar]
  70. Breman P. How automation technology may contribute to the quality of life in the elderly care: An integrated personalized care approach. Int. J. Integr. Care 2021 21 S1 214 10.5334/ijic.ICIC20320
    [Google Scholar]
  71. Albertsen N. Sommer T.G. Olsen T.M. Prischl A. Kallerup H. Andersen S. Polypharmacy and potential drug–drug interactions among Greenland’s care home residents. Ther. Adv. Drug Saf. 2022 13 20420986221103918 10.1177/20420986221103918 35784387
    [Google Scholar]
  72. Fabbri C. Zohar J. Serretti A. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. Prog. Neuropsychopharmacol. Biol. Psychiatry 2018 86 36 44 10.1016/j.pnpbp.2018.05.007 29777729
    [Google Scholar]
  73. Higher-than-recommended doses of antipsychotic medications may not benefit people with schizophrenia and may increase side effects PsycEXTRA Dataset 2007 10.1037/e603782007‑025
    [Google Scholar]
  74. Access, cost, and quality issues in medication use Preventing Medi-cation Errors and Improving Drug Therapy Outcomes 101 145 10.1201/9780203010730‑12
    [Google Scholar]
  75. Pardiñas A.F. Owen M.J. Walters J.T.R. Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron 2021 109 24 3914 3929 10.1016/j.neuron.2021.09.011 34619094
    [Google Scholar]
  76. Wagner E. Luykx J.J. Strube W. Hasan A. Challenges, unmet needs and future directions – A critical evaluation of the clinical trial landscape in schizophrenia research. Expert Rev. Clin. Pharmacol. 2024 17 1 11 18 10.1080/17512433.2023.2293996 38087450
    [Google Scholar]
  77. Solmi M. Murru A. Pacchiarotti I. Undurraga J. Veronese N. Fornaro M. Stubbs B. Monaco F. Vieta E. Seeman M. Correll C. Carvalho A. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review. Ther. Clin. Risk Manag. 2017 13 757 777 10.2147/TCRM.S117321 28721057
    [Google Scholar]
  78. Paul C. Innovations in medication therapy management: The role of artificial intelligence and digital health technologies 2023 Available from: https://iipseries.org/assets/docupload/rsl20247558F1CECCB46B4.pdf
/content/journals/cdm/10.2174/0113892002382047250930160449
Loading
The Intricacies of Polypharmacy and Drug Interactions in Schizophrenia Treatment
Bentham Science Publishers ; https://doi.org/10.2174/0113892002382047250930160449
/content/journals/cdm/10.2174/0113892002382047250930160449
/content/journals/cdm/10.2174/0113892002382047250930160449
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: clinicaloutcomes ; drug-drug interactions ; schizophrenia ; Polypharmacy ; pharmacogenetics ; antipsychotics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test